Fig. 2From: Effect of empagliflozin on ketone bodies in patients with stable chronic heart failureChange in β-hydroxybutyrate (β-OHB) between baseline and after 12 weeks of treatment with empagliflozin (left side) and between baseline and after 12 weeks of treatment with placebo (right side)Back to article page